Supplementary Tables S1-S4 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS⁺ CD4⁺ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Supplementary Table 1: List of antibodies used in the mass cytometry panel Supplementary Table 2: Number of immune cells analysed by CYTOF in our cohort Supplementary Table 3: Demographic and clinical characteristics of the CyTOF UCLA cohort (n=27), the Total UCLA cohort (n=97) and the Total KEYNOTE-001 (n=495) of non-small cell lung cancer patients Supplementary Table 4: Cox's proportional hazards model for overall survival in NSCLC patients treated with pembrolizumab in KEYNOTE-001